ebola

news, أهم الأخبار, صحة,

Start a new serum England to fight the Ebola virus experience

01/07/2015 - 11:06

Scientists from the University of Oxford began injection in healthy volunteers with serum new anti-Ebola virus, and scientists have conducted independent experiments in September last year on the use of another vaccine to combat the virus.

The latter include the experiment 72 volunteers between the ages of 18 to 50 years, and has shown preliminary experiments conducted on monkeys that the new vaccine, which companies Janssen Pharmaceutical subsidiary, "Johnson & Johnson", provides complete protection from Ebola virus.

And volunteers in Oxford are the first sample of people get this new vaccine.

Said Matthew Snape, from the Oxford Group for Vaccines of the Department of Pediatrics University: "We aim immunize all participants during the month," and added: "The main objective is to stand over the safety of this vaccine."

Experience and include a group of volunteers received an additional dose activated after a month or two of the initial injection, and will be carried out similar small trials in the United States and three African countries not affected by the outbreak of the Ebola virus.

The aim of the creation of the first dose of the immune system, and promote the second dose activated efficiency and responsiveness, and stressed organizers of the experiment that the vaccine can not cause injury to any person with the virus, and will be measured by the extent of the immune system in response to the vaccine in a year.

She said the company "Johnson & Johnson" She hopes that a broader range of experiences in Africa, Europe and the second phase begins in three months, and then allow the vaccine for use in Liberia, Guinea and Sierra Leone by mid-2015, the company says it has been available million doses of the vaccine this year .

Led health crisis caused by the outbreak of the Ebola virus to accelerate the pace of research on access to vaccines to combat the virus.

In September, an independent team began to follow the Jenner Institute in Oxford experience on Ebola vaccine developed by the company "Glascosmezqlin" and the National Institutes of Health in the United States.

It is scheduled to announce the results of the experiment soon, and there is a plan to fortify the workers involved in the fight against the virus in the medical field in the affected countries in West Africa later this month.

American "Merck" company also bought the rights to a third serum anti-Ebola development of the company "Neulenk Genetics' technology Alehioah.waijera experience this serum in Switzerland.

The experiment was conducted in Geneva had stopped last month after complaining of some volunteers from joint pains, but the experiment resumed this week by giving the participants in the experiment with lower doses.

Russia has also developed other Omassala to combat the virus, and Snape said: "The fact that there are at least three vaccines to combat Ebola place of safety tests is good news."

He added: "The presence of several vaccines are making progress through clinical trials increases the likelihood of the ability of vaccines manufacturers to meet the demand of the case had to make a group of fortifications," he said, "there are more vaccines and more companies operating in the good news."